{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:42:59Z","timestamp":1778802179330,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.clinre.2013.11.006","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T04:04:56Z","timestamp":1388721896000},"page":"219-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Raltitrexed-based chemotherapy for advanced colorectal cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Y.","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinre.2013.11.006_bib0005","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"7\u20138","key":"10.1016\/j.clinre.2013.11.006_bib0010","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/0959-8049(95)00166-G","article-title":"ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer","volume":"31A","author":"Jackman","year":"1995","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.clinre.2013.11.006_bib0015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/01.coc.0000128722.41587.19","article-title":"Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study","volume":"27","author":"Ferrari","year":"2004","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2013.11.006_bib0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2004.09.022","article-title":"Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer","volume":"41","author":"Planting","year":"2005","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1016\/j.clinre.2013.11.006_bib0025","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4\u20136","key":"10.1016\/j.clinre.2013.11.006_bib0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000086968","article-title":"A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma","volume":"68","author":"Francois","year":"2005","journal-title":"Oncology"},{"issue":"Suppl. 1","key":"10.1016\/j.clinre.2013.11.006_bib0035","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(99)00042-8","article-title":"Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials","volume":"35","author":"Schwartz","year":"1999","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clinre.2013.11.006_bib0040","first-page":"81","article-title":"A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer","volume":"27","author":"Nishisho","year":"2000","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3","key":"10.1016\/j.clinre.2013.11.006_bib0045","first-page":"154","article-title":"A patient preference study comparing raltitrexed (\u201cTomudex\u201d) and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side effects and administration attributes","volume":"8","author":"Young","year":"1999","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"10.1016\/j.clinre.2013.11.006_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"9","key":"10.1016\/j.clinre.2013.11.006_bib0055","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/oxfordjournals.annonc.a010800","article-title":"Final results of a randomised trial comparing \u201cTomudex\u201d (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. \u201cTomudex\u201d Colorectal Cancer Study Group","volume":"7","author":"Cunningham","year":"1996","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.clinre.2013.11.006_bib0060","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","article-title":"Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group","volume":"16","author":"Cocconi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9317","key":"10.1016\/j.clinre.2013.11.006_bib0065","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(02)08514-8","article-title":"Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial","volume":"359","author":"Maughan","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clinre.2013.11.006_bib0070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000094357","article-title":"Randomised trial comparing three different schedules of infusional 5-FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Federation Francophone de Cancerologie Digestive (FFCD) 9601 trial","volume":"70","author":"Ducreux","year":"2006","journal-title":"Oncology"},{"issue":"15","key":"10.1016\/j.clinre.2013.11.006_bib0075","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.ejca.2008.07.002","article-title":"Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)","volume":"44","author":"Popov","year":"2008","journal-title":"Eur J Cancer"},{"issue":"09","key":"10.1016\/j.clinre.2013.11.006_bib0080","first-page":"711","article-title":"Comparison of raltitrexed plus oxaliplatinl and 5-fluorouracil\/leucovorin plus oxaliplatinl in treatment of advanced colorectal carcinoma","volume":"34","author":"Wu","year":"2007","journal-title":"China Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2013.11.006_bib0085","first-page":"7","article-title":"Raltitrexed versus fluorouracil\/leucovorin combined with oxaliplatin for advanced colorectal cancer: a prospective study","volume":"34","author":"Xue","year":"2011","journal-title":"Chin J Postgrad Med"},{"issue":"10","key":"10.1016\/j.clinre.2013.11.006_bib0090","first-page":"61","article-title":"Raltitrexed plus oxaliplatinl in treatment of senile advanced colorectal carcinoma","volume":"22","author":"Ning","year":"2011","journal-title":"Hainan Med J"},{"issue":"07","key":"10.1016\/j.clinre.2013.11.006_bib0095","first-page":"88","article-title":"Raltitrexed combined with oxaliplatinl in the treatment of advanced colorectal cancer","volume":"16","author":"Fu","year":"2012","journal-title":"J Clin Med Pract"},{"issue":"8","key":"10.1016\/j.clinre.2013.11.006_bib0100","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12094-012-0843-x","article-title":"A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer","volume":"14","author":"Gravalos","year":"2012","journal-title":"Clin Transl Oncol"},{"issue":"01","key":"10.1016\/j.clinre.2013.11.006_bib0105","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/cco.2017.01.01","article-title":"Randomized multicenter phase III trial of oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouraeil and leucovorin for advanced colorectal cancel","volume":"17","author":"Wang","year":"2012","journal-title":"Chin Clin Oncol"},{"issue":"2 Suppl. 5","key":"10.1016\/j.clinre.2013.11.006_bib0110","first-page":"4","article-title":"mechanism of action and antineoplastic activity","volume":"25","author":"Raymond","year":"1998","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2013.11.006_bib0115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/annonc\/mdf054","article-title":"current clinical status and future directions","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clinre.2013.11.006_bib0120","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.2000.18.11.2293","article-title":"dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer","volume":"18","author":"Fizazi","year":"2000","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2013.11.006_bib0125","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/1097-0142(20010401)91:7<1264::AID-CNCR1127>3.0.CO;2-X","article-title":"Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I\u2013II trial","volume":"91","author":"Scheithauer","year":"2001","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clinre.2013.11.006_bib0130","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdf183","article-title":"Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients","volume":"13","author":"Seitz","year":"2002","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2013.11.006_bib0135","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/030089160409000205","article-title":"Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer","volume":"90","author":"Cortinovis","year":"2004","journal-title":"Tumori"},{"issue":"5","key":"10.1016\/j.clinre.2013.11.006_bib0140","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/annonc\/mdf091","article-title":"Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)","volume":"13","author":"Cascinu","year":"2002","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2013.11.006_bib0145","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00001813-200308000-00005","article-title":"Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors","volume":"14","author":"Massacesi","year":"2003","journal-title":"Anticancer Drugs"},{"issue":"10","key":"10.1016\/j.clinre.2013.11.006_bib0150","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ejca.2013.03.004","article-title":"Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history","volume":"49","author":"Kelly","year":"2013","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clinre.2013.11.006_bib0155","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0959-8049(01)00413-0","article-title":"Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. A review of phase II\/III trials","volume":"38","author":"Cunningham","year":"2002","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clinre.2013.11.006_bib0160","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0163278702025001006","article-title":"To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data","volume":"25","author":"Stewart","year":"2002","journal-title":"Eval Health Prof"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740113002647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740113002647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:18:17Z","timestamp":1761895097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740113002647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S2210740113002647"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2013.11.006","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Raltitrexed-based chemotherapy for advanced colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2013.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}